Does Race Have an Impact on CLL Care? What the Latest Data? | Adam Kittai, MD #EHA2025

Does Race Have an Impact on CLL Care? What the Latest Data? | Adam Kittai, MD #EHA2025
Racial Disparities in CLL Treatment: What the Latest Data Tells Us | Adam Kittai, MD | #EHA 2025
Advancing ET & Myelofibrosis Care: mutCALR Antibody Therapy | John Mascarenhas, MD | #EHA 2025
Advancing ET & Myelofibrosis Care: mutCALR Antibody Therapy | John Mascarenhas, MD | #EHA 2025
Could Clonotypic B Cells Be the Key to Myeloma & AL Amyloidosis Origins? | Bruno Paiva, PhD | EHA25
Could Clonotypic B Cells Be the Key to Myeloma & AL Amyloidosis Origins? | Bruno Paiva, PhD | EHA25
When can I expect to feel better after transplant?
All-Oral Myeloma Combo: Mezigdomide + Tazemetostat or Trametinib | Paul Richardson, MD | EHA 2025
All-Oral Myeloma Combo: Mezigdomide + Tazemetostat or Trametinib | Paul Richardson, MD | EHA 2025
Slowing CAR-T Cell Expansion with Steroids 2 Prevent Delayed Neurotoxicity | Yi Lin, MD | #EHA2025
Slowing CAR-T Cell Expansion with Steroids 2 Prevent Delayed Neurotoxicity | Yi Lin, MD | #EHA2025
How long will I be immunocompromised? How can I prevent infection after transplant?
How long is the average stay for an ASCT? How will the doctor know when I am able to return home or no longer come for daily clinic visits?
Belantamab Mafodotin Updates & How to Manage Eye Side Effects | Evangelos Terpos, MD, PhD | #EHA2025
Belantamab Mafodotin Updates & How to Manage Eye Side Effects | Evangelos Terpos, MD, PhD | #EHA2025
New Insights into High-Risk Amyloidosis Staging | Jahanzaib Khwaja, MD, FRCPath | #EHA2025
New Insights into High-Risk Amyloidosis Staging | Jahanzaib Khwaja, MD, FRCPath | #EHA2025